Şahin Anılgan · Diabetes/metabolism research and reviews 2026 · narrative review · n=?

Type 5 Diabetes Mellitus: Pathophysiology, Clinical Phenotype, and Nutritional Management.

Cited 0 times in the scientific literature.

Level 5 - mechanism / opinion, no new human data

Narrative review synthesizing existing concepts without primary data or systematic review methodology

PubMed 42531222 · doi:10.1002/dmrr.70212 · record verified 2026-08-29

What was done

The authors synthesized published evidence regarding Type 5 Diabetes Mellitus (T5DM), a form of diabetes linked to chronic undernutrition and recognized by the International Diabetes Federation in 2025. The review examines epidemiology, Developmental Origins of Health and Disease (DOHaD) pathophysiology, clinical features, diagnostic differentiation from other diabetes types, and nutritional management strategies based entirely on the existing literature.

What was found

The abstract provides no quantitative metrics, statistical analyses, or sample numbers. It describes qualitative findings: - Onset typically occurs before age 30 in young, lean individuals with low body mass index and sarcopenia. - Patients exhibit marked insulinopenia and severe hyperglycemia but lack diabetes-associated autoantibodies and demonstrate resistance to ketosis. - Early-life undernutrition impairs pancreatic morphogenesis, permanently reducing functional beta-cell mass via epigenetic programming. - Preserved peripheral insulin sensitivity creates a high risk for iatrogenic hypoglycemia, necessitating cautious low-dose insulin alongside energy, protein, and micronutrient repletion.

Why it matters

This review characterizes an under-recognized, non-autoimmune insulin-deficient diabetes phenotype prevalent in low- and middle-income regions, cautioning against standard Type 1 or Type 2 management algorithms that risk iatrogenic hypoglycemia.

Limits

As an unsystematic narrative review, it presents no primary data, standardized diagnostic cutoffs, or controlled trial results. Abstract details do not provide specific outcome measures, treatment response rates, or quantitative comparative data against classical diabetes phenotypes.

Cited by